ISIS. Alnylam, through its Affiliate or a Third Party collaborator, has commenced an IND-Enabling Study for [**] product candidate as set forth in Section 5.2(b) of the Listed Alnylam Third Party Agreement with Isis Pharmaceuticals, Inc. Alnylam presently has the exclusive right under the “Isis Patents” (as defined on Schedule C) and the right to grant sublicenses under the Listed Alnylam Third Party Agreement with Isis Pharmaceuticals, Inc.
ISIS. MERCK and ISIS will cooperate fully and will provide each other and the independent patent legal counsel with any information or assistance that any party may reasonably request. Outside patent legal counsel shall keep MERCK and ISIS informed of developments in any such action or proceeding. Decisions on whether to initiate such a proceeding and the course of action in such proceeding, including settlement negotiations and terms, shall be made by mutual agreement of ISIS and MERCK.
ISIS. Strategic Collaboration & License Agreement between Isis Pharmaceuticals, Inc. (“Isis”), and Alnylam, dated March 11, 2004, as supplemented or amended by letter agreements dated March 9, 2004 (as amended by letter agreement dated October 28, 2005), March 11, 2004, and June 10, 2005 (as amended, “Isis Agreement”) Limitations on License Grant (Section 5.1)
ISIS. 4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group [see comments]. Lancet 1995;345:669-685.
ISIS. As used herein, the term "Isis" shall mean Isis Pharmaceuticals, Inc., and its successors in interest.
ISIS. FXIRx-2 in its finished form is the finished drug product containing the Development Candidate designated under the ISIS-FXIRx-2 Program as an active pharmaceutical ingredient.
ISIS. FXIRx-2 in its finished form is the finished drug product containing the Development Candidate designated under the ISIS-FXIRx-2 Program as an active pharmaceutical ingredient. “ISIS-FXIRx-2 Program” has the meaning set forth in Section 2.1.1. “[***]. “[***]. “Isis Indemnitees” has the meaning set forth in Section 10.1. “Isis In-License Agreements” means the agreements listed on Appendix 4. If, as a result of Section 2.2.2, where Bayer has elected to use Bayer Opt-In Technology, or as a result of Section 7.11.3(a) where Isis elects to obtain Additional Core IP, amendments to Appendix 4 are required and Appendix 4 will be updated to include any additional Isis In-License Agreements. “Isis Internal ASO Safety Database” has the meaning set forth in Section 6.6(a). “Isis Know-How” means any Know-How, including Isis’ interest in any Jointly-Owned Program Know-How, owned, used, developed by, or licensed to Isis or its Affiliates, in each case to the extent Controlled by Isis or its Affiliates on the Effective Date or at any time during the Agreement Term. Isis Know-How does not include the Isis Manufacturing and Analytical Know-How. 86 Confidential “Isis Manufacturing and Analytical Know-How” means Know-How, including Isis’ interest in any Jointly-Owned Program Know-How, that relates to the synthesis or analysis of a Product regardless of sequence or chemical modification, owned, used, developed by, or licensed to Isis or its Affiliates, in each case to the extent Controlled by Isis or its Affiliates on the Effective Date or at any time during the Agreement Term. Isis Manufacturing and Analytical Know-How do not include the Isis Know-How. “Isis Manufacturing and Analytical Patents” means Patent Rights, including Isis’ interest in any Jointly-Owned Program Patents, that claim Manufacturing Technology owned, used, developed by, or licensed to Isis or its Affiliates, in each case to the extent Controlled by Isis or its Affiliates on the Effective Date or at any time during the Agreement Term. A list of Isis Manufacturing and Analytical Patents as of the Effective Date is set forth on Appendix 6 attached hereto. Appendix 6 will be updated during the Agreement Term with any additional Isis Manufacturing and Analytical Patents claiming technology incorporated into a Product. Isis Manufacturing and Analytical Patents do not include the Isis Product-Specific Patents or the Isis Core Technology Patents. “Isis Owned Patents” has the meaning set forth in Section 9.2.2. “Is...
ISIS. Isis is a party to this agreement solely for the purposes of accepting its obligations under, and being able to enforce, for its benefit, the terms of, clauses 2.3, 13 and 19.6, subject to the limitations of liability in clause 21.
ISIS. A history. Princeton: Princeton University Press, 2016.
